Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.51 |
| ▸ | DPP7 | Q9UHL4 | 8/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 6/20 | 0.43 |
| ▸ | DPP9 | Q86TI2 | 6/20 | 0.43 |
| ▸ | DPP4 | P27487 | 2/20 | 0.43 |
| ▸ | ABHD6 | Q9BV23 | 5/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4728102 | 0.80 | ESR1 (0.45) | ESR1ESR2HDAC8HDAC6ABHD6 | |
| SCHEMBL25604135 | 0.79 | ESR2 (0.77) | ESR1ESR2HDAC8HDAC6ABHD6 | |
| SCHEMBL13439632 | 0.78 | KCNJ1 (0.48) | ESR1ESR2ABHD6HSP90AA1HSP90AB1 | |
| SCHEMBL31670368 | 0.78 | HDAC6 (0.55) | ESR1ESR2DPP7HDAC8HDAC6 | |
| SCHEMBL27305602 | 0.78 | NPC1 (0.43) | DPP7DPP8DPP9DPP4HSP90AA1 | |
| SCHEMBL29986831 | 0.78 | ESR1 (0.54) | ESR1ESR2DPP7HDAC8HDAC6 | |
| SCHEMBL25199618 | 0.78 | ESR1 (0.57) | ESR1ESR2HDAC8HDAC6DPP4 | |
| SCHEMBL5913288 | 0.78 | ESR1 (0.54) | ESR1ESR2DPP7HDAC8HDAC6 | |
| SCHEMBL30412058 | 0.78 | ESR1 (0.57) | ESR1ESR2HDAC8HDAC6DPP4 | |
| SCHEMBL25200187 | 0.78 | ABHD6 (0.65) | ESR1ESR2DPP7HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250144094-A1 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | ERASCA, INC. | 2025-05-08 | — | — | US | disclosed |
| EP-4433059-A1 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | Erasca, Inc. (US) | 2024-09-25 | — | — | EP | disclosed |
| WO-2023215494-A1 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | ERASCA, INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023215494-A1 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | ERASCA, INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023087027-A1 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | ERASCA, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| WO-2023087027-A1 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | ERASCA, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250144094-A1 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | ULK1, ULK2, ULK3 | ESR1 3000/4885ESR2 2354/4885DPP7 2080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.